Viviana Frantellizzi

Prof. Viviana Frantellizzi

Sapienza University of Rome
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 August 2015 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
MPMassimiliano Pacilio
Massimiliano Pacilio
GVGuido Ventroni
Guido Ventroni
GVGiuseppe De Vincentis
Giuseppe De Vincentis
BCBartolomeo Cassano
Bartolomeo Cassano
RPRosanna Pellegrini
Rosanna Pellegrini
LMLucio Mango
Lucio Mango

8 February 2020 in Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Closed access
PDF file
VFViviana Frantellizzi
Viviana Frantellizzi
MCMiriam Conte
Miriam Conte
MPMariano Pontico
Mariano Pontico
APArianna Pani
Arianna Pani
RPRoberto Pani
Roberto Pani
GVGiuseppe De Vincentis
Giuseppe De Vincentis

6 January 2020 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
VFViviana Frantellizzi
Viviana Frantellizzi
APArianna Pani
Arianna Pani
MRMaria Ricci
Maria Ricci
NLNicoletta Locuratolo
Nicoletta Locuratolo
FFFrancesco Fattapposta
Francesco Fattapposta
GVGiuseppe De Vincentis
Giuseppe De Vincentis
Cerebrovascular diseases are well established causes of cognitive impairment. Different etiologic entities, such as vascular dementia (VaD), vascular cognitive impairment, subcortical (ischemic) VaD, and vascular cognitive disorder, are included in the umbrella definition of vascular cognitive impairment and dementia (VCID). Because of the variability of VCID clinical presentation, there is no agreement on criteria defining the neuropathological threshold of this disorder. In fact, VCID is characterized by cerebral hemodynamic alteration which ranges from decreased cerebral blood flow to small vessels disease and involves a multifactorial process that leads to demyelination and gliosis, including blood-brain barrier disruption, hypoxia, and hypoperfusion, oxidative stress, neuroinflammation and alteration on neurovascular unit coupling, cerebral microbleeds, or superficial siderosis. Numerous criteria for the definition of VaD have been described: the National Institute of Neurological Disorders and Stroke Association Internationale pour Recherche'-et-l’Enseignement en Neurosciences criteria, the State of California Alzheimer’s Disease Diagnostic and Treatment Centers criteria, DSM-V criteria, the Diagnostic Criteria for Vascular Cognitive Disorders (a VASCOG Statement), and Vascular Impairment of Cognition Classification Consensus Study. Neuroimaging is fundamental for definition and diagnosis of VCID and should be used to assess the extent, location, and type of vascular lesions. MRI is the most sensible technique, especially if used according to standardized protocols, even if CT plays an important role in several conditions. Functional neuroimaging, in particular functional MRI and PET, may facilitate differential diagnosis among different forms of dementia. This systematic review aims to explore the state of the art and future perspective of non-invasive diagnostics of VCID.

13 August 2020 in Cancer Biotherapy and Radiopharmaceuticals
Verified
Journal Article
Closed access
VFViviana Frantellizzi
Viviana Frantellizzi
LCLaura Cosma
Laura Cosma
GBGabriele Brunotti
Gabriele Brunotti
APArianna Pani
Arianna Pani
ASAngela Spanu
Angela Spanu
GVGiuseppe De Vincentis
Giuseppe De Vincentis
Targeted alpha therapy (TAT) can deliver high localized burden of radiation selectively to cancer cells as well as the tumor microenvironment, while minimizing toxicity to normal surrounding cell. Radium-223 ( 223 Ra), the first-in-class α-emitter approved for bone metastatic castration-resistant prostate cancer has shown the ability to prolong patient survival. Targeted Thorium-227 ( 227 Th) conjugates represent a new class of therapeutic radiopharmaceuticals for TAT. They are comprised of the α-emitter 227 Th complexed to a chelator conjugated to a tumor-targeting monoclonal antibody. In this review, the authors will focus out interest on this therapeutic agent. In recent studies 227 Th-labeled radioimmunoconjugates showed a relevant stability both in serum and vivo conditions with a significant antigen-dependent inhibition of cell growth. Unlike 223 Ra, the parent radionuclide 227 Th can form highly stable chelator complexes and is therefore amenable to targeted radioimmunotherapy. The authors discuss the future potential role of 227 Th TAT in the treatment of several solid as well as hematologic malignancies.

6 September 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
Matteo BaucknehtMatteo Bauckneht
Matteo Bauckneht
SRSara Elena Rebuzzi
Sara Elena Rebuzzi
ASAlessio Signori
Alessio Signori
VFViviana Frantellizzi
Viviana Frantellizzi
VMVeronica Murianni
Veronica Murianni
GFGiuseppe Fornarini
Giuseppe Fornarini
Purpose: To combine peripheral blood indices and clinical factors in a prognostic score for metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 dichloride ([223Ra]RaCl2).Patients and methods: Baseline neutrophil-to-lymphocyte ratio (NLR), derived NLR (donor), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), systemic inflammation index (SII), Eastern Cooperative Oncology Group performance status (ECOG PS), Gleason score (GS) group, number of bone metastases, prostate-specific antigen (PSA), alkaline phosphatase (ALP), line of therapy, previous chemotherapy, and the presence of lymphadenopathies were collected from seven Italian centers between 2013 and 2020. Lab and clinical data were assessed in correlation with the overall survival (OS). Inflammatory indices were then included separately in the multivariable analyses with the prognostic clinical factors. The model with the highest discriminative ability (c-index) was chosen to develop the BIO-Ra score.Results: Five hundred and nineteen mCRPC patients (median OS: 19.9 months) were enrolled. Higher NLR, dNLR, PLR, and SII and lower LMR predicted worse OS (all with ap < 0.001). The multivariable model including NLR, ECOG PS, number of bone metastases, ALP, and PSA (c-index: 0.724) was chosen to develop the BIO-Ra score. Using the Schneeweiss scoring system, the BIO-Ra score identified three prognostic groups (36%, 27.3%, and 36.6% patients, respectively) with distinct median OS (31, 26.6, and 9.6 months, respectively; hazard ratio: 1.62,p = 0.008 for group 2 vs. 1 and 5.77,p < 0.001 for group 3 vs. 1).Conclusions: The BIO-Ra score represents an easy and widely applicable tool for the prognostic stratification of mCRPC patients treated with [223Ra]RaCl2with no additional costs.

Verified
Journal Article
Open access
PDF file
MSMarko Magdi Abdou Sidrak
Marko Magdi Abdou Sidrak
MFMaria Silvia De Feo
Maria Silvia De Feo
FCFerdinando Corica
Ferdinando Corica
JGJoana Gorica
Joana Gorica
MCMiriam Conte
Miriam Conte
VFViviana Frantellizzi
Viviana Frantellizzi
Cancer is the leading cause of death around the globe, followed by heart disease and stroke, with the highest mortality to this day. We have reached great levels of understanding of how these various types of cancer operate at a cellular level and this has brought us to what we call “precision medicine” where every diagnostic examination and the therapeutic procedure is tailored to the patient. FAPI is among the new tracers that can be used to assess and treat many types of cancer. The aim of this review was to gather all the known literature on FAPI theranostics. A MEDLINE search was conducted on four web libraries, PUBMED, Cochrane, Scopus, and Web of Sciences. All of the available articles that included both diagnoses and therapy with FAPI tracers were collected and put through the CASP (Critical Appraisal Skills Programme) questionnaire for systematic reviewing. A total of 8 records were deemed suitable for CASP review, ranging from 2018 to November 2022. These studies were put through the CASP diagnostic checklist, in order to assess the goal of the study, diagnostic and reference tests, results, descriptions of the patient sample, and future applications. Sample sizes were heterogeneous, both for size as well as for tumor type. Only one author studied a single type of cancer with FAPI tracers. Progression of disease was the most common outcome, and no relevant collateral effects were noted. Although FAPI theranostics is still in its infancy and lacks solid grounds to be brought into clinical practice, it does not show any collateral effects that prohibit administration to patients, thus far, and has good tolerability profiles.